{"id":4253,"date":"2026-09-05T17:03:17","date_gmt":"2026-09-05T14:03:17","guid":{"rendered":"https:\/\/wniss.com\/?p=4253"},"modified":"2026-09-05T17:04:09","modified_gmt":"2026-09-05T14:04:09","slug":"reviewing-new-depression-medication-2022-development","status":"publish","type":"post","link":"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/","title":{"rendered":"Reviewing New Depression Medication 2022 Development"},"content":{"rendered":"\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"><h2><span class=\"ez-toc-section\" id=\"Reviewing_New_Depression_Medication_2022_Development_Major_Advances_and_Emerging_Treatments\"><\/span>Reviewing New Depression Medication 2022 Development: Major Advances and Emerging Treatments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>New depression medication 2022 development<\/strong> marked an important period in psychiatric research, with scientists moving beyond traditional serotonin-based antidepressants toward treatments that target new brain pathways. The year introduced a significant FDA-approved option, expanded research into rapid-acting therapies, and accelerated interest in medications affecting glutamate, dopamine, and neuroplasticity mechanisms. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 58px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">U.S. Food and Drug Administration<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Reviewing_New_Depression_Medication_2022_Development_Major_Advances_and_Emerging_Treatments\" >Reviewing New Depression Medication 2022 Development: Major Advances and Emerging Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#The_Changing_Landscape_of_Depression_Medication_Development\" >The Changing Landscape of Depression Medication Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Auvelity_The_Most_Significant_FDA_Antidepressant_Approval_of_2022\" >Auvelity: The Most Significant FDA Antidepressant Approval of 2022<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#How_Auvelity_Works\" >How Auvelity Works<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Potential_Benefits\" >Potential Benefits<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Zuranolone_A_New_Direction_in_Depression_Treatment_Research\" >Zuranolone: A New Direction in Depression Treatment Research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Moving_Beyond_Serotonin_New_Biological_Targets\" >Moving Beyond Serotonin: New Biological Targets<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Glutamate-Based_Treatments\" >Glutamate-Based Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Dopamine-Based_Approaches\" >Dopamine-Based Approaches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Neuroplasticity_Research\" >Neuroplasticity Research<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Ansofaxine_and_Triple-Action_Antidepressant_Development\" >Ansofaxine and Triple-Action Antidepressant Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Treatment-Resistant_Depression_The_Main_Focus_of_Innovation\" >Treatment-Resistant Depression: The Main Focus of Innovation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#NMDA_Receptor_Modulation\" >NMDA Receptor Modulation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Combining_Medication_With_Brain-Based_Therapies\" >Combining Medication With Brain-Based Therapies<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#How_New_Depression_Medications_Differ_From_Older_Antidepressants\" >How New Depression Medications Differ From Older Antidepressants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Challenges_Facing_New_Depression_Medication_Development\" >Challenges Facing New Depression Medication Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Safety_Monitoring\" >Safety Monitoring<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Individual_Differences\" >Individual Differences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Long-Term_Evidence\" >Long-Term Evidence<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Future_Direction_of_Depression_Treatment\" >Future Direction of Depression Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Frequently_Asked_Questions_FAQs\" >Frequently Asked Questions (FAQs)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#1_What_was_the_most_important_new_depression_medication_development_in_2022\" >1. What was the most important new depression medication development in 2022?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#2_Are_new_antidepressants_replacing_SSRIs\" >2. Are new antidepressants replacing SSRIs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#3_Do_newer_depression_medications_work_faster\" >3. Do newer depression medications work faster?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#4_What_is_the_difference_between_traditional_and_newer_antidepressants\" >4. What is the difference between traditional and newer antidepressants?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#5_Should_someone_change_their_antidepressant_because_of_new_developments\" >5. Should someone change their antidepressant because of new developments?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Medical_Disclaimer\" >Medical Disclaimer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/wniss.com\/en-gb\/reviewing-new-depression-medication-2022-development\/#Source_Reference\" >Source Reference<\/a><\/li><\/ul><\/nav><\/div>\n\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Medication \/ Development<\/th><th class=\"last:pe-10\">Main Mechanism<\/th><th class=\"last:pe-10\">Depression Application<\/th><th class=\"last:pe-10\">Development Status in 2022<\/th><\/tr><\/thead><tbody><tr><td>Auvelity (dextromethorphan + bupropion)<\/td><td>NMDA receptor modulation + norepinephrine\/dopamine effects<\/td><td>Major depressive disorder (MDD)<\/td><td>FDA approved in 2022<\/td><\/tr><tr><td>Zuranolone (SAGE-217)<\/td><td>Neuroactive steroid affecting GABA-A receptors<\/td><td>Depression, especially postpartum depression research<\/td><td>Late-stage clinical development<\/td><\/tr><tr><td>Ansofaxine (Toludesvenlafaxine)<\/td><td>Triple reuptake inhibition of serotonin, norepinephrine, dopamine<\/td><td>Major depressive disorder<\/td><td>Approved in China; international development ongoing<\/td><\/tr><tr><td>REL-1017 (Esmethadone)<\/td><td>NMDA receptor modulation<\/td><td>Treatment-resistant depression research<\/td><td>Clinical trials<\/td><\/tr><tr><td>Seltorexant<\/td><td>Orexin receptor targeting<\/td><td>Depression with sleep-related symptoms<\/td><td>Clinical development<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 48.8906px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<p><span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 86px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Reddit<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Changing_Landscape_of_Depression_Medication_Development\"><\/span>The Changing Landscape of Depression Medication Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For decades, depression treatment relied heavily on medications that influenced serotonin pathways, including selective serotonin reuptake inhibitors (SSRIs). While these medications remain effective for many patients, researchers recognized the need for treatments that work faster, help treatment-resistant depression, and address different biological causes.<\/p>\n<p>The <strong>new depression medication 2022 development<\/strong> trend focused on several scientific goals:<\/p>\n<ul>\n<li>\n<p>Faster symptom improvement<\/p>\n<\/li>\n<li>\n<p>New neurological targets<\/p>\n<\/li>\n<li>\n<p>Reduced treatment resistance<\/p>\n<\/li>\n<li>\n<p>Better personalization of therapy<\/p>\n<\/li>\n<li>\n<p>Improved side-effect profiles<\/p>\n<\/li>\n<\/ul>\n<p>Traditional antidepressants often require several weeks before noticeable improvement occurs. Newer approaches attempt to influence brain circuits more directly, especially pathways related to glutamate, GABA, and neural plasticity. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 100px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Verywell Mind<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Auvelity_The_Most_Significant_FDA_Antidepressant_Approval_of_2022\"><\/span>Auvelity: The Most Significant FDA Antidepressant Approval of 2022<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>One of the biggest developments in 2022 was the approval of <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Axsome Therapeutics<\/span><\/span>\u2019s Auvelity, a combination of dextromethorphan and bupropion, for major depressive disorder. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 75px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Reuters<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<p>Unlike conventional antidepressants that primarily affect serotonin, Auvelity works through a different pathway:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_Auvelity_Works\"><\/span>How Auvelity Works<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dextromethorphan influences:<\/p>\n<ul>\n<li>\n<p>NMDA receptors associated with glutamate activity<\/p>\n<\/li>\n<li>\n<p>Sigma-1 receptors involved in neural signaling<\/p>\n<\/li>\n<\/ul>\n<p>Bupropion helps by affecting:<\/p>\n<ul>\n<li>\n<p>Dopamine activity<\/p>\n<\/li>\n<li>\n<p>Norepinephrine activity<\/p>\n<\/li>\n<\/ul>\n<p>This combination represents a move toward medications designed around broader brain network regulation rather than a single neurotransmitter system.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Potential_Benefits\"><\/span>Potential Benefits<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Researchers developed this approach to address limitations seen with older medications, including:<\/p>\n<ul>\n<li>\n<p>Delayed therapeutic response<\/p>\n<\/li>\n<li>\n<p>Limited effectiveness in some patients<\/p>\n<\/li>\n<li>\n<p>Persistent depressive symptoms despite treatment<\/p>\n<\/li>\n<\/ul>\n<p>However, individual responses vary, and Auvelity is not considered a universal replacement for SSRIs or other antidepressants.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Zuranolone_A_New_Direction_in_Depression_Treatment_Research\"><\/span>Zuranolone: A New Direction in Depression Treatment Research<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Another important 2022 development involved zuranolone, a medication designed around neurosteroid biology.<\/p>\n<p>Unlike many antidepressants that influence serotonin or norepinephrine, zuranolone targets the GABA system through modulation of GABA-A receptors.<\/p>\n<p>Researchers investigated its potential for:<\/p>\n<ul>\n<li>\n<p>Major depressive disorder<\/p>\n<\/li>\n<li>\n<p>Postpartum depression<\/p>\n<\/li>\n<li>\n<p>Rapid symptom relief<\/p>\n<\/li>\n<\/ul>\n<p>The interest in zuranolone came from studies suggesting that certain neurosteroid pathways may influence mood regulation, stress responses, and emotional balance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Moving_Beyond_Serotonin_New_Biological_Targets\"><\/span>Moving Beyond Serotonin: New Biological Targets<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The development of new depression medication options in 2022 reflected a broader understanding of depression as a complex neurological condition.<\/p>\n<p>Researchers explored several targets:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Glutamate-Based_Treatments\"><\/span>Glutamate-Based Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Glutamate is the brain\u2019s primary excitatory neurotransmitter. Medications affecting glutamate signaling became a major research focus because of their possible rapid antidepressant effects.<\/p>\n<p>Potential advantages include:<\/p>\n<ul>\n<li>\n<p>Faster symptom improvement<\/p>\n<\/li>\n<li>\n<p>Different mechanism from SSRIs<\/p>\n<\/li>\n<li>\n<p>Possible benefits for treatment-resistant depression<\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Dopamine-Based_Approaches\"><\/span>Dopamine-Based Approaches<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dopamine contributes to:<\/p>\n<ul>\n<li>\n<p>Motivation<\/p>\n<\/li>\n<li>\n<p>Reward processing<\/p>\n<\/li>\n<li>\n<p>Energy regulation<\/p>\n<\/li>\n<\/ul>\n<p>Some newer medications attempt to improve depressive symptoms linked with low motivation and reduced pleasure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Neuroplasticity_Research\"><\/span>Neuroplasticity Research<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Modern depression research increasingly examines how medications may encourage the brain to create stronger adaptive connections.<\/p>\n<p>This approach differs from older models focused only on correcting neurotransmitter imbalance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ansofaxine_and_Triple-Action_Antidepressant_Development\"><\/span>Ansofaxine and Triple-Action Antidepressant Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ansofaxine, also known as toludesvenlafaxine, attracted attention during 2022 because it represented a potential new triple-action antidepressant.<\/p>\n<p>The medication is designed to influence:<\/p>\n<ul>\n<li>\n<p>Serotonin<\/p>\n<\/li>\n<li>\n<p>Norepinephrine<\/p>\n<\/li>\n<li>\n<p>Dopamine<\/p>\n<\/li>\n<\/ul>\n<p>This mechanism resembles earlier SNRI medications but adds dopamine activity.<\/p>\n<p>Supporters of this approach suggest that targeting three systems may provide broader symptom improvement, particularly for patients experiencing:<\/p>\n<ul>\n<li>\n<p>Low energy<\/p>\n<\/li>\n<li>\n<p>Reduced concentration<\/p>\n<\/li>\n<li>\n<p>Loss of motivation<\/p>\n<\/li>\n<\/ul>\n<p>Clinical development continued internationally after approval in China. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 54px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Reddit<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Treatment-Resistant_Depression_The_Main_Focus_of_Innovation\"><\/span>Treatment-Resistant Depression: The Main Focus of Innovation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A major challenge in psychiatry remains treatment-resistant depression, where patients do not achieve sufficient improvement after standard therapies.<\/p>\n<p>New medication development focused heavily on this group.<\/p>\n<p>Emerging strategies included:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"NMDA_Receptor_Modulation\"><\/span>NMDA Receptor Modulation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>NMDA-related medications aim to influence glutamate signaling and potentially create faster antidepressant effects.<\/p>\n<p>Examples studied around this period included:<\/p>\n<ul>\n<li>\n<p>REL-1017<\/p>\n<\/li>\n<li>\n<p>Other glutamate-modulating compounds<\/p>\n<\/li>\n<\/ul>\n<p><span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 54px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Reddit<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Combining_Medication_With_Brain-Based_Therapies\"><\/span>Combining Medication With Brain-Based Therapies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Researchers also investigated combinations involving:<\/p>\n<ul>\n<li>\n<p>Medication management<\/p>\n<\/li>\n<li>\n<p>Psychotherapy<\/p>\n<\/li>\n<li>\n<p>Transcranial magnetic stimulation (TMS)<\/p>\n<\/li>\n<li>\n<p>Lifestyle interventions<\/p>\n<\/li>\n<\/ul>\n<p>Personalized approaches became increasingly important because depression varies significantly between individuals. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">arXiv<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_New_Depression_Medications_Differ_From_Older_Antidepressants\"><\/span>How New Depression Medications Differ From Older Antidepressants<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Feature<\/th><th class=\"last:pe-10\">Traditional Antidepressants<\/th><th class=\"last:pe-10\">Newer Development Approaches<\/th><\/tr><\/thead><tbody><tr><td>Main targets<\/td><td>Mainly serotonin and norepinephrine<\/td><td>Glutamate, GABA, dopamine, neurosteroids<\/td><\/tr><tr><td>Response speed<\/td><td>Often weeks<\/td><td>Some designed for faster effects<\/td><\/tr><tr><td>Main use<\/td><td>Common depression treatment<\/td><td>Depression subtypes and resistant cases<\/td><\/tr><tr><td>Research goal<\/td><td>Symptom reduction<\/td><td>Personalized and biologically targeted treatment<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 64.875px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Challenges_Facing_New_Depression_Medication_Development\"><\/span>Challenges Facing New Depression Medication Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although 2022 brought promising advances, several challenges remain.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Safety_Monitoring\"><\/span>Safety Monitoring<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New mechanisms require extensive monitoring because changing brain signaling can create unexpected effects.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Individual_Differences\"><\/span>Individual Differences<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A medication that works well for one person may not work for another due to:<\/p>\n<ul>\n<li>\n<p>Genetics<\/p>\n<\/li>\n<li>\n<p>Brain chemistry<\/p>\n<\/li>\n<li>\n<p>Medical history<\/p>\n<\/li>\n<li>\n<p>Previous treatments<\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Long-Term_Evidence\"><\/span>Long-Term Evidence<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Many newer medications require years of observation to fully understand:<\/p>\n<ul>\n<li>\n<p>Long-term effectiveness<\/p>\n<\/li>\n<li>\n<p>Safety profile<\/p>\n<\/li>\n<li>\n<p>Appropriate patient selection<\/p>\n<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Future_Direction_of_Depression_Treatment\"><\/span>Future Direction of Depression Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The future of depression medication development is likely to involve precision psychiatry.<\/p>\n<p>Future treatments may combine:<\/p>\n<ul>\n<li>\n<p>Genetic information<\/p>\n<\/li>\n<li>\n<p>Brain imaging<\/p>\n<\/li>\n<li>\n<p>Biomarker testing<\/p>\n<\/li>\n<li>\n<p>Artificial intelligence prediction models<\/p>\n<\/li>\n<li>\n<p>Individual symptom patterns<\/p>\n<\/li>\n<\/ul>\n<p>Researchers are working toward reducing the current trial-and-error approach in antidepressant selection. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 48px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">arXiv<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span>Frequently Asked Questions (FAQs)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_What_was_the_most_important_new_depression_medication_development_in_2022\"><\/span>1. What was the most important new depression medication development in 2022?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The approval of Auvelity for major depressive disorder was one of the most notable developments because it introduced a different mechanism from traditional serotonin-focused antidepressants. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 58px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Reuters<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Are_new_antidepressants_replacing_SSRIs\"><\/span>2. Are new antidepressants replacing SSRIs?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No. SSRIs remain important treatments for many people. New medications are intended to expand available options, especially for individuals who do not respond adequately to existing treatments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Do_newer_depression_medications_work_faster\"><\/span>3. Do newer depression medications work faster?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Some newer treatments are designed to produce faster improvements, but response varies between individuals and depends on the medication and clinical situation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_What_is_the_difference_between_traditional_and_newer_antidepressants\"><\/span>4. What is the difference between traditional and newer antidepressants?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Traditional medications mainly affect serotonin and norepinephrine, while newer approaches may target glutamate, GABA, dopamine, or neurosteroid pathways.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Should_someone_change_their_antidepressant_because_of_new_developments\"><\/span>5. Should someone change their antidepressant because of new developments?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Medication changes should always be discussed with a qualified healthcare professional. A newer medication is not automatically better for every person.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Medical_Disclaimer\"><\/span>Medical Disclaimer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The information provided in this article is for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Do not use this information to diagnose or treat any health condition. Always consult a doctor before starting, stopping, or changing any medication or treatment plan.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Source_Reference\"><\/span>Source Reference<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Source: <span class=\"decorated-link\">https:\/\/en.wikipedia.org\/wiki\/Depression_(mood)<span aria-hidden=\"true\" class=\"ms-0.5 inline-block align-middle leading-none select-none\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"block h-[0.75em] w-[0.75em] stroke-current stroke-[0.75] select-none\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#304883\" fill=\"currentColor\"><\/use><\/svg><\/span><\/span><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Reviewing New Depression Medication 2022 Development: Major Advances and Emerging Treatments New depression medication 2022 development marked an important period in psychiatric research, with scientists moving beyond traditional serotonin-based antidepressants toward treatments that target new brain pathways. The year introduced a significant FDA-approved option, expanded research into rapid-acting therapies, and accelerated interest in medications affecting&#8230;<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[730],"tags":[],"class_list":["post-4253","post","type-post","status-publish","format-standard","hentry","category-depression"],"acf":[],"_links":{"self":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/comments?post=4253"}],"version-history":[{"count":2,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4253\/revisions"}],"predecessor-version":[{"id":6097,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4253\/revisions\/6097"}],"wp:attachment":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media?parent=4253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/categories?post=4253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/tags?post=4253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}